ARYLALKYLAMINE COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER Russian patent published in 2020 - IPC A61K31/137 A61K31/343 A61P35/00 

Abstract RU 2714893 C2

FIELD: medicine.

SUBSTANCE: group of inventions relates to the field of medicine and pharmaceuticals. First invention represents a method for preventing or treating cancer or cancer metastasis in a subject, comprising administering a therapeutic amount of a compound of formula II, or its pharmaceutically acceptable salt,

II,

where in formula II: Q is a substituted or unsubstituted bicyclic group which consists of one benzene ring and a saturated or unsaturated five-membered ring which contains one or more heteroatoms; R1 is C1-4-alkyl; R2 is hydrogen, C1-4-alkyl, C2-4-alkenyl, C2-4-alkynyl, C2-4-alkylcarbonyl or C6-10-aryl; R3 is hydrogen, methyl or ethyl. Second invention represents a drug containing said compound and an adjuvant.

EFFECT: group of inventions enables use of neurone activity amplification compounds for preventing or treating cancer diseases.

16 cl, 20 dwg, 9 ex, 4 tbl

Similar patents RU2714893C2

Title Year Author Number
ARYLALKYLAMINE COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER 2015
  • Knoll Jozhef
  • Mikya Ildiko
  • Ferdinandi Peter
  • Shuler Dezhe
  • Shaff Zhuzhanna
  • Ekkhardt Shandor
RU2731102C2
METHOD OF SYNTHESIS OF PHENYLALKYLAMINES OF THEIRS PHARMACOLOGICALLY ACCEPTABLE SALTS 1989
  • Jozhef Knoll[Hu]
  • Antal Shimai[Hu]
  • Eva Sinn'Ei[Hu]
  • Eva Shomfai[Hu]
  • Zoltan Terek[Hu]
  • Karoj Mozholitsh[Hu]
  • Janosh Bergmann[Hu]
RU2007384C1
SELECTIVE INVERSE SEROTONIN 2A/2C RECEPTOR AGONISTS APPLICABLES AS THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISORDERS 2008
  • Uehjner Dehvid M.
  • Dehvis Robert E.
  • Brehnn Mark R.
  • Nehsh Norman
  • Anderson Karl-Magnus A.
  • Ul'Dam Alan K.
RU2465267C2
SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS, USED AS THERAPEUTICS FOR NEURODEGENERATIVES DISEASES 2004
  • Uehjner Dehvid M.
  • Dehvis Robert E.
  • Brehnn Mark R.
RU2332401C2
APPLICATION OF K-252A DERIVATIVES TO TREAT DISORDERS OF PERIPHERAL OR CENTRAL NERVOUS SYSTEMS AND EXCESSIVE CYTOKINE OUTPUT 1997
  • Ehngber Tomas M.
  • Khaun Forrest A.
  • Saporito Majkl S.
  • Ehjmon Lajza D.
  • Miller Mehtt'Ju S.
  • Najt Ehrnest Ml.
RU2183959C2
ENDOGENIC PHARMACEUTICAL COMPOSITION PREPARED ON BASIS OF GOAL-SEEKING ACTIVATION OF HUMORAL MEDIATORS OF BRAIN CORTEX NERVE ENDING 2003
  • Pinigina N.M.
  • Latserus L.A.
  • Latserus F.Eh.
RU2244928C2
METHOD OF TREATMENT OR PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES BY MEANS OF COMPOUNDS POSSESSING SELECTIVITY WITH RESPECT TO ALPHA-3-SUBUNIT OF BENZODIAZEPINE RECEPTOR 2004
  • Langen Barbara
  • Rundfel'Dt Kris
  • Dost Rita
  • Ljuddens Khartmut
  • Rabe Khol'Ger
RU2354377C2
CONJUGATE, MEDICATION AND METHODS OF TREATMENT AND/OR PREVENTION OF DEPRESSION AND DISEASE ASSOCIATED WITH LEWY BODIES CONCRETION 2011
  • Alvarado Urbina Gabriel
  • Artigas Peres Fransesk
  • Bortolossi Biassoni Analiya
  • Vila Bover Mikel
  • Montefeltro Andres Pablo
RU2664452C2
PSYCHOTIC DISORDER SIMULATION METHOD 2004
  • Kozlovskij Vladimir Leonidovich
RU2366464C2
PHARMACEUTICAL COMPOSITION AND A METHOD OF ITS PREPARING, METHOD OF TREATMENT OF DISORDERS CAUSED BY NEURODEGENERATIVE PROCESSES 1992
  • Kal'Man Mad'Jar
  • Jozhef Gaal
  • Ishtvan Siraki
  • Jozhef Lend'El
  • Anna Sabo
  • Katalin Marmaroshi
  • Ishtvan Khermets
  • Ishtvan Satmari
  • Zoltan Terek
  • Peter Kermetsi
RU2125448C1

RU 2 714 893 C2

Authors

Knoll, Jozhef

Mikya, Ildiko

Ferdinandi, Peter

Shuler, Dezhe

Shaff, Zhuzhanna

Ekkhardt, Shandor

Dates

2020-02-20Published

2015-12-07Filed